Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$5.54
$5.55
$2.61
$5.65
$290.24M1.25376,318 shsN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$20.85
+5.1%
$20.61
$13.30
$30.03
$1.24B0.93394,504 shs830,394 shs
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$19.61
+1.2%
$19.24
$13.22
$45.37
$1.13B-1.89922,092 shs544,304 shs
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$1.15
+3.6%
$0.66
$0.35
$1.95
$1.27B1.8576.75 million shs51.16 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00%0.00%0.00%0.00%-0.89%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
0.00%+3.12%-5.01%+27.13%-11.91%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
0.00%-2.53%+7.33%-20.12%-50.53%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.00%+11.65%+63.63%+159.95%-39.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.8371 of 5 stars
3.52.00.00.02.44.20.0
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.6298 of 5 stars
3.53.00.00.01.91.70.6
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.4385 of 5 stars
3.11.00.00.03.21.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00
N/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00
Buy$41.2097.60% Upside
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
3.00
Buy$75.71286.10% Upside
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.20
Hold$1.9266.67% Upside

Current Analyst Ratings Breakdown

Latest ALIM, ELVN, TLRY, and GPCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $60.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$92.00 ➝ $90.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$89.00 ➝ $87.00
7/29/2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Zelman & Associates
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
7/2/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $48.00
6/23/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$65.00
6/23/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$89.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$99.68M2.91N/AN/A$0.88 per share6.30
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$6.34 per shareN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$15.10 per shareN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$821.31M1.54$0.14 per share7.96$1.40 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$89.02M-$2.000.00N/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$122.53M-$1.050.00N/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$2.19B-$2.310.00N/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)

Latest ALIM, ELVN, TLRY, and GPCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.53-$0.49+$0.04-$0.49N/AN/A
8/6/2025Q2 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.28-$0.36-$0.08-$0.36N/AN/A
7/28/2025Q4 2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
1.80
2.79
2.62
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
32.58
32.58
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
20.48
20.48
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.20
2.46
1.49

Institutional Ownership

CompanyInstitutional Ownership
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
99.83%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
9.35%

Insider Ownership

CompanyInsider Ownership
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
31.40%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
25.90%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
5.60%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
15052.39 million35.94 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5059.24 million43.89 millionOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13657.60 million54.37 millionOptionable
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2,8421.10 billion1.09 billionOptionable

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Trading Up 2.3% - What's Next?
Tilray Brands (NASDAQ:TLRY) Trading Down 3.3% - Time to Sell?
Logo visible on smartphone screen with website page
Tilray's High Hopes: The Catalyst Driving Cannabis Stocks
...
Top Cannabis Stocks To Watch Today - August 20th
Cannabis Stocks To Follow Today - August 19th
Tilray Brands (NASDAQ:TLRY) Shares Gap Up - Here's Why
Cannabis Stocks Worth Watching - August 16th
Best Canadian Cannabis Stocks in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alimera Sciences stock logo

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$20.85 +1.01 (+5.09%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$20.88 +0.03 (+0.14%)
As of 08/22/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$19.61 +0.24 (+1.24%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$19.92 +0.32 (+1.61%)
As of 08/22/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tilray Brands stock logo

Tilray Brands NASDAQ:TLRY

$1.15 +0.04 (+3.60%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.43%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.